Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.
Kevin E. Noonan
Advertisement
Kevin E. Noonan, PhD, is a partner at McDonnell Boehnen Hulbert & Berghoff LLP.
Articles by Kevin E. Noonan
A controversial naming convention attempts to explain important distinctions between biologic drugs and their biosimilar counterparts.
Advertisement
Latest Updated Articles
Biosimilar Names Prove Difficult to DefineMarch 1st 2017
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
3
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
4
FDA Grants RMAT and Fast Track Designations to AbelZeta’s Bispecific CAR-T Prizlon-cel in Large B-Cell Lymphoma
5